LYEL Lyell Immunopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1806952 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-63.4%
TTM net income YoY21.6%
TTM EPS YoY44.6%
Revenue 3-yr CAGR-93.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,783,580.0%
Net margin-1,701,066.7%
FCF margin-933,100.0%
EBITDA margin-1,723,546.7%
Returns
ROE-97.8%
ROA-74.8%
ROIC (approx.)-138.0%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets29.6%
Debt / equity0.00x
Current ratio4.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.55x
Accruals ratio-34.0%
Payout ratio—
Capex / revenue4,766.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $36,000 | $61,000 |
| R&D expense | $158.68M | $171.60M |
| SG&A expense | $45.13M | $52.04M |
| Operating income | -$269.40M | -$358.75M |
| Income tax | $0 | — |
| Net income | -$274.45M | -$342.99M |
| EBITDA | -$257.87M | -$339.12M |
| EPS (basic) | -16.06 | -26.23 |
| EPS (diluted) | -16.06 | -26.23 |
| Weighted avg. shares (diluted) | 17.09M | 13.07M |
| Balance sheet | ||
| Cash & equivalents | $60.18M | $107.29M |
| Short-term investments | $187.04M | $264.93M |
| Current assets | $260.94M | $379.59M |
| PP&E, net | $34.77M | $48.20M |
| Total assets | $340.05M | $490.86M |
| Current liabilities | $49.41M | $53.79M |
| Total liabilities | $91.85M | $108.03M |
| Shareholders' equity | $248.20M | $382.82M |
| Shares outstanding | 21.25M | 14.74M |
| Cash flow statement | ||
| Operating cash flow | -$150.02M | -$162.39M |
| Capital expenditure | $780,000 | $464,000 |
| Free cash flow | -$150.80M | -$162.86M |
| Investing cash flow | $54.10M | $122.42M |
| Financing cash flow | $50.41M | $1.33M |
| Depreciation & amortization | $11.54M | $19.63M |
| Stock-based compensation | $41.83M | $33.14M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.